--News Direct--
Recce Pharmaceuticals Ltd (ASX:RCE) CEO James Graham tells Proactive that the company has been given a boost from the Australian Patent Office, which has issued notification of ‘intent to grant’ for the first of Recce’s new Patent Family 4 anti-infectives. The patent covers the 'Process for Preparation of Biologically Active Copolymer' and expires in 2041.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/recce-pharmaceuticals-further-strengthens-market-monopoly-for-anti-infectives-576059273
